Novartis Message Board - Msg: 13786854

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novartis

NVS 122.63

+0.7%

Oct 30 3:59 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mark H. Bornfeld who wrote ()	5/26/2000 8:16:00 PM
From: Timothy Kross	of 296

Exelon, the new Alzheimer's drug from Novartis is about to hit the streets. My Novartis rep was in today, telling me that I can now write for the drug. This drug will be used for the elderly patient with dementia. Because it increases cognitive function and increases the patient's ability to function in activities of daily living, there is a pressing need for such a drug. The main competitor, Aricept, has been the only drug available in this category until now. From initial marketing data, Exelon may be an improvement over Aricept. I started using the drug today for the first time. It will be several months to titrate dose up to the maximum levels allowed. I await the clinical response for my patients.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next